PLSE vs. ANIK, SRDX, NPCE, SKIN, TCMD, BVS, OSUR, GUTS, LYRA, and CVRX
Should you be buying Pulse Biosciences stock or one of its competitors? The main competitors of Pulse Biosciences include Anika Therapeutics (ANIK), Surmodics (SRDX), NeuroPace (NPCE), Beauty Health (SKIN), Tactile Systems Technology (TCMD), Bioventus (BVS), OraSure Technologies (OSUR), Fractyl Health (GUTS), Lyra Therapeutics (LYRA), and CVRx (CVRX). These companies are all part of the "surgical & medical instruments" industry.
Anika Therapeutics (NASDAQ:ANIK) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment.
Pulse Biosciences has a net margin of 0.00% compared to Pulse Biosciences' net margin of -49.60%. Pulse Biosciences' return on equity of -2.10% beat Anika Therapeutics' return on equity.
Anika Therapeutics received 52 more outperform votes than Pulse Biosciences when rated by MarketBeat users. However, 65.17% of users gave Pulse Biosciences an outperform vote while only 64.30% of users gave Anika Therapeutics an outperform vote.
Anika Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.
91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 5.9% of Anika Therapeutics shares are owned by company insiders. Comparatively, 69.7% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Anika Therapeutics presently has a consensus target price of $29.50, suggesting a potential upside of 15.37%. Given Pulse Biosciences' higher possible upside, equities analysts plainly believe Anika Therapeutics is more favorable than Pulse Biosciences.
Pulse Biosciences has lower revenue, but higher earnings than Anika Therapeutics. Pulse Biosciences is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Anika Therapeutics had 3 more articles in the media than Pulse Biosciences. MarketBeat recorded 4 mentions for Anika Therapeutics and 1 mentions for Pulse Biosciences. Anika Therapeutics' average media sentiment score of 0.00 beat Pulse Biosciences' score of -0.02 indicating that Pulse Biosciences is being referred to more favorably in the news media.
Summary
Anika Therapeutics beats Pulse Biosciences on 9 of the 17 factors compared between the two stocks.
Get Pulse Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulse Biosciences Competitors List
Related Companies and Tools
